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Axillobifemoral bypass (Ax-bFB) has become a treatment option for managing bilateral lower extremity critical ischemia caused by aortoiliac disease in high-risk patients who would not be expected to tolerate the more durable aortobifemoral bypass (ABFB). Although Ax-bFB is associated with a lower mortality rate than ABFB in high-risk patients, its effectiveness may be significantly impaired by several factors1,2: the need for general anesthesia, dissection of an unaffected vascular bed with potential upper extremity embolization, a high rate of graft infection, and compromised patency rates that require additional operations? ,3-s Moreover, the potential for poor hemodynamic and functional improvement as a result of insufficient donor artery flow and the long grafts required may further hamper procedural success, [8] [9] [10] [11] [12] Ohki et aL 985 Fig, 1 . EVG and delivery systems. A, Endovascular thin-walled PTFE graft. A Palmaz balloonexpandable stent (S) is sutured to graft with four diametrically opposed " U " sutures (two on each side), which permit one half of the stent to protrude from graft. B, Double balloon catheter introducer/delivery system used for delivery and deployment of endovascular stented grafts. In this system, the introducer catheter is equipped with two separate balloon catheters. Balloon A functions as a mechanism to form a tapered tip to catheter system and also allows pressurization of the flexible sheath (C) after saline is injected from port D. Second balloon B functions to deploy overlying Palmaz stent (S). With expansion of balloon B, EVG (G) becomes firmly fixed to underlying arterial wall. V, hemostafic valve mechanism. C, Alternative delivery system consisting of single balloon catheter with two balloons on a single shaft. First balloon serves as a tip balloon (A), and stent-graft complex is mounted on to independent deploying balloon (B).
Endovascular techniques that are catheter-and guidewire-based are another less-invasive treatment option. Percutaneous balloon angioplasty with or without the use of vascular stents has been extensively used for managing aortoiliac occlusive disease. Thus far, however, these catheter-based techniques have proven utility only for. short-segment lesions in patients who have minimal symptoms, and they have not been proved effective for treating patients who have multilevel critical ischemia. [13] [14] [15] [16] The introduction of endovascular grafts (EVGs) appears to have extended the potential uses of angioplasty and stenting to include the treatment of critical ischemia as a result of aortoiliac occlusive disease. Although favorable short-term and middle-term results have been shown in unilateral iliac disease, bilateral iliac occlusions were typically more technically challenging and suggested further procedure modifications 22 Porter et al. 2a were the first to recognize the potential of using endovascular techniques for the treatment of bilateral aortoiliac disease. Their initial report suggested a role for balloor, angioplasty in the treatment of a stenotic lesion in the donor iliac arteit¢ with the subsequent performance ofa femorofemoral bypass procedure (FFB). Although these authors emphasized the efficacy of balloon angloplasty in their seminal paper, this technique did not have broad application because success was limited to treating focal common iliac artery disease. We have combined EVGs and FFBs for the treatment of bilateral long-segment aortoiliac occlusive disease that causes limb-threatening ischemia in those patients who have multiple medical illnesses or have previously undergone abdominal aortic surgery. This method not only simplifies the complex endovascular procedure that is required in bilateral reconstruction, but may also achieve better hemodynamic, anglographic, and clinical results.
METHODS
Patients. Between March 1994 and December 1995, seven patients who had fimb-threatening ischernia and tissue necrosis as a result of aortoiliac and femoropopliteal occlusive disease were treated at the Montefiore Medical Center with a unilateral endovascular aortofemoral or iliofemoral EVG in combination with a standard FFB reconstruction. Four were men and three were women; their ages ranged from 59 to 77 years (mean, 69 years). All patients had grade 5 ischemia (SVS/ISCVS criteria24), and had No. 2 multiple, coexisting medical problems, including a M/70 history of a previous myocardial infarction in all cases, No. 3 recent myocardial infarction, congestive heart failure, F/70 and chronic obstructive pulmonary disease (Table I) . Four patients (57%) had a history of one or more No. 4 abdominal vascular operations. Pulse volume record-F/77 ings (PVRs), ankle-brachial indexes, and angiograms No. 5 with femoropopliteal and tibial runoff views were M/71 performed in all patients before and after each inter-No. 6 vention. The patency of the superficial femoral artery F/59 and the distal runoff score were determined from the No. 7 preoperative angiograms according to the SVS/ M/71 ISCVS criteria. Each patient's risk and severity scores for operative treatment were calculated in accordance with Rutherford's criteria and the SVS/ISCVS standards (Table 1) . 24, 25 EVG devices. The EVGs used in this study were composed of Palmaz balloon-expandable stents (30 ram, Johnson and Johnson Interventional Systems, Warren, N.J.) and 6-mm thin-walled polytetrafluoroethylene (PTFE) grafts (Wi. Gore and Associates, Flagstaff, Ariz.; and IMPRA, Inc., Tempe, Ariz.). Each stent was attached to the proximal end of the PTFE graft by four CV-6 PTFE sutures so that one half of the stent protruded from the end of the graft (Fig. 1, A) . After suturing the graft to the stent, the stent-graft complex was mounted on to an angioplasty balloon by manually crimping the stent over the balloon surface. The delivery system consisted of an 8 mm × 3 cm angioplasty balloon (Blue Max or PEMT, Medi-tech Corp., Watertown, Mass.) and a second balloon catheter (tip balloon). The entire stent, graft, and balloon complex was then wrapped around the shaft of the tip balloon and inserted into a 14F delivery sheath ( Fig. 1, B ). The 6 man × 4 cm tip balloon was adjusted so that one-third of the tapered portion of the balloon protruded from the distal portion of the delivery sheath. A modified form of this delivery system consisted of a dual balloon catheter (tip balloon and stent deploying balloon) on a single shaft ( Fig. 1 , C). In both delivery system configurations, inflation of the tip balloon sealed the distal end of the sheath, allowing sheath pressurization for variable flexibility and pushability and providing a tapered, smooth transition to the end of the defivery sheath. Determination of side for EVG insertion and location of stent deployment. The ifiac artery in which the EVG is deployed and the positioning of the proximal stent are determined by preoperative angiographic findings. The deployment of the EVG will likely result in the occlusion of all of the small branches along the vessel that is covered by the graft. The presence and quality of the internal iliac artery will, therefore, influence the side of EVG access and the site of deployment. Similarly, the length and degree of the common or external iliac artery disease will often determine the technical difficulty associated with vessel recaualization. Generally, it is easier and safer to racanalize through a stenotic lesion than through an occluded lesion. In addition, shorter lesions are easier to recanalize. Using the algorithm outlined in Fig. 2 , the classification of disease patterns (type I, internal iliac artery is occluded or severely diseased bilaterally; type II, a goodquality internal iliac artery is present on one side; type III, a goo&quality internal lilac artery is present bilaterally), the side to be used for EVG insertion, and the location of the proximal stent were determined. Operative technique. Open dissection and exposure of the femoral arterial access site were performed. After systemic heparinization, all iliac arteries were successfully recanalized with a 0.035-inch hydrophilic guidewire (Glidewire, Medi-tech, Inc.) and an angled directional catheter under fluoroscopic guidance (BV 212, Philips, The Netherlands; or OEC Diasonics model 9000, OEC Medical Systems, Inc., Salt Lake City, Utah) ( Fig. 3 ). After successful wire passage, an 8-mm-diameter angioplasty balloon was passed over the wire, and the iliac artery was dilated to a diameter of 8 mm along the entire length of the vessel (Fig. 4 ). The previously prepared EVG device was then inserted into the newly created tract within the arterial wall over the same guidewire ( Fig.  5 ). Once the fixation stem could be seen fluoroscopically to be located at the appropriate predetermined site, the tip balloon was deflated, and the sheath was then partially retracted to allow proximal stent exposure and deployment (Fig. 6 ). The delivery sheath was then completely withdrawn, permitting the redundant portion of the distal end of the EVG to emerge from the arteriotomy in the access vessel. The distal, redundant portion of the graft was then cut to an appropriate length and was endoluminally handsewn into the patent, distal runoffvessel ( Fig. 7) . A 6-ram externally supported thin-walled PTFE graft (W.L. Gore and Associates) was used for the FFB in each patient. The arteriotomy site used for the insertion of the EVG served as the proximal anastomotic site of the FFB. The graft was subcutaneously tunneled to the contralateral side and the recipient anastomosis was performed in a standard fashion to the patent, distal nmoffvessel ( Fig. 8 ).
Combined-segment occlusive disease was simultaneously treated with either a femoropopliteal bypass or a patch proftmdaplasty procedure. Those patients who had tissue necrosis or a nonhealing ulcer tmderwent either simultaneous minor amputation or debridemenr. An intraoperative completion anglogram was performed in all patients.
Follow-up studies. A follow-up arteriographic scan was performed inamediately afte r surgery in six of the seven patients within the first week. All patients underwent postoperative PVRs and a determination of the ankle~brachial index. The PVR amplitudes that were obtained before and after surgery were compared for each patient to determine the hemodynamic improvement that occurred. Additional PVRs, ankle-brachial indexes, and color duplex ultrasonographic evaluations were performed at regular inter- vals (3 months, 6 months, and every 6 months thereafter). A long-term course of anticoagulafion medication was not used. Table I , the mean patient risk score was 1.4 + 0.5 (mean + SD), and the mean runoff scores were 5.7 + 3 and 4.9 + 3 for right and left limbs, respectively.
RESULTS

As shown in
Coexisting comorbid illnesses precluded the use of general anesthesia in six of the seven patients, and either epidural (5) or local anesthesia (1) was used. Technical success of recanalization and device insertion was achieved in each case in which it was attempted. The mean operating time for recanalization and EVG insertion was 2.5 hours, and the mean blood loss was 182 ml (Table II) . Four patients were classified as type I, two as type II, and one as type III (Table II; Fig. 9 ). The EVGs were anastomosed distally to the common femoral artery (3), the deep femoral artery (3), and the superficial femoral artery (1) . The EVG lengths ranged from 21 cm to 32 cm (mean, 26 cm; Table II ). Mid-graft stenosis (2) from either inadequate graft expansion (1) or extraluminal compression (1) of the prosthesis was corrected by balloon dilatation (1) of the narrowed graft segment, with the insertion of an additional balloon expandable stent (1) within the endovascular prosthetic graft.
The anastomotic site of the recipient artery for the FFB grafts was the common femoral artery in five patients and the deep femoral artery in two patients. Combined-segment occlusive disease was simultaneously treated in five of the patients with a total of eight supplemental procedures (two femoropopliteal bypass procedures; six profundaplasty procedures). Four of the patients underwent a partial foot amputation at the conclusion of the arterial reconstructive procedures (one bilateral transmetatarsal; three single/multiple toe amputations).
After endovascular aortofemoral reconstruction and, in some instances, a supplementary conventional infrainguinal surgical bypass or profundaplasty procedure, the ankle-brachial indexes significantly improved (p < 0.05, Student's paired t test) from a mean of 0.24 + 0.3 to 0.64 -+ 1.3 in the ipsilateral limb with an EVG and from a mean of 0.09 + 0.2 to 0.70 + 0.2 in the contralateral limb. As shown in Fig.  10 , the thigh PVR amplitudes also improved from a mean of 9.0 + 3 mm to a mean of 29.9 -+ 7 mm in the limb ipsilateral to the EVG and from a mean of 6.1 _+ 2 mm to a mean of 26A -+ 4 mm in the contralateral limb (p < 0.05, Student's paired t test): Fig. 3 . Surgical procedure for endovascular grafting The side for graft insertion is selected by using algorithm shown in Fig. 2 . Because this case is type I, stenosed side is chosen for recanalization. 7F introducer sheath is inserted via an open arteriotomy in femoral artery. Care must be taken to puncture artery at the center of the planned anastomosis site for subsequent FFB. Recanalization wire and directional catheter are inserted through the sheath. An effort is made to direct recanalization wire and catheter within the stenosed lumen or within the intraintimal layer of occluded artery.
There were no early or late graft failures during the follow-up period, which ranged from 9 to 28 months (mean, 17 months). One patient died o f myocardial infarction 19 months after surgery. Limb salvage and w o u n d healing were achieved in all cases. Complete relief o f ischemic symptoms, including rest pain, was achieved in all patients. After surgery, the changes in clinical status were all + 3 (markedly improved) according to the Rutherford criteria 2s (Table II) .
There were no major complications, and minor complications were limited to one groin hematoma that resolved without intervention. T w o external iliac arteries that were severely calcified perforated during . 7F introducer sheath is removed while recanalizanon wire is held in a stable positron. Using scissors, arteriotomy is extended to a size that will accommodate a I4F delivery sheath. Under fluoroscopic control, delivery sheath is inserted over wire and a radiopaque Palmaz stent is positioned at preselected site. In this example of type I disease, proximal stent is deployed within distal aorta. It is crucial to place the stent above the proximal end of the atherosclerotic plaque.
76%) as the operative indication. 26,28,29 These patients tend to be relatively younger and healthier than those patients who have advanced ischemic disease, and they may he expected to have a better outcome from treatment. These good results may not extend to all patient groups. For example, in a recent series Mason et al.2 reported a morbidity rate of 30% and a mortality rate of 7% in a group of relatively high-risk patients who underwent ABFB. Accordingly, patients who have critical leg ischemia that requires a multilevel arterial reconstruction for advanced, bilateral aortoiliac atherosclerotic disease who also have severe medical illnesses or have had previous abdominal vascular surgery are likely to be at an even higher risk for perioperative complications from an ABFB. Fig. 6 . After accurate posinonmg of device, tip balloon is deflated and outer sheath is partially retracted so that ennre stent is exposed. With inflation of the second balloon, the EVG becomes firmly fixed to the underlying arterial wall. Balloon catheter is then used to gently dilate the PTFE graft in a serial descending segmental fashion as the balloon is withdrawn.
Ax-bFB has been the procedure of choice for treating patients who have bilateral aortoiliac occlusive disease and who are high surgical risks. 1,2,4-12,31-35 Although this procedure is less physiologically stressful than ABFB and has been associated with a lower mortality rate than ABFB in the high-risk population, it is generally considered to be a compromise procedure with relatively poor patency rates.l,2,4,7-9,11,12,31 Those investigators who do not recommend the use of Ax-bFB have reported primary patency rates of 54% to 63% and 47% to 68% at 1 and 5 years, respectively. 4,7-9,11,12 On the basis of these results, it has been suggested that the indications for Ax-bFB should be restricted to patients who have a major contraindication to the use of ABFB. Alternatively, Parsonnet et al. 35 dures should be considered as an alternative procedure to ABFB, even ha patients who are not high surgical risks. This concept has been supported by E1-Massry et al.s3 and Taylor et al., 32 who demonstrated impressive primary patency rates of 78% and 74% at 5 years, respectively, using an externally supported PTFE graft. Solely on the basis of these excellent patency rates, Taylor et al. s2 concluded that Ax-bFB is an appropriate technique that deserves more widespread use.
Although patency rates are clearly an important factor in evaluating the effectiveness of Ax-bFB, several additional concerns limit the value of this procedure compared with the techniques described in the present study. The first is the need for general anesthesia. Although still controversial, recent data ob- tained from well-designed and carefully conducted randomized, prospective studies have demonstrated substantially reduced morbidity and mortality rates when epidnral anesthesia was used instead of general anesthesia, a6-39 Yeager et al. s7 randomized 53 highrisk surgical patients to either general anesthesia or epidural anesthesia and identified a sevenfold increase in the incidence of major infection in the general anesthesia group. This study also proved a significant benefit to the use of epidural anesthesia in terms of the incidence of overall morbidity, respiratory failure, and hospital cost. The significant benefits of epidural anesthesia over general anesthesia have been confirmed by another randomized, prospective study, s8'39 Endovascular grafting 0fthe lilac arteries may be performed under local or epidnral anesthesia, which may be a major advantage over conventional treatu~ent options in medically ill patients. Another factor that limits the effectiveness of Ax-bFB in comparison with the techniques described in
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December 1996 this study is the insufficient hemodynamic improvement that is seen in the affected limb after Ax-bFB. 8-12 O'Donnell et al. 11 investigated the hemodynamic improvement after Ax-bFB and found that when it was applied for limb salvage, the resolution of symptoms (i.e., healing of foot lesions or relief of rest pain) was achieved in only 24% of the cases. These investigators also measured the plethysmographic amplitude of the limb before and after surgery and showed that the Ax-bFB had no significant effect on this measurement. These findings are also consistent with a number of other reports that have focused on the same issues. 8-1°, 12 The mechanism for this phenomenon is thought to be related to the relatively small donor artery and the high flow resistance caused by the lengthy bypass graft. In comparison, the hemodynamic and functional outcome after endovascnlar grafting in the present study was very encouraging. In all cases the symptoms were completely relieved, along with a 3.3-fold increase in the PVR amplitude in the thigh. These results may be in part a result of the short in-line reconstruction used for endovascular iliac bypass. The final limiting factor for axillobifemoral reconstruction is the known wide variety of graft-related complications that occur after Ax-bFB, including graft infection, upper-arm ischemia as a result of thromboembolism, or disruption of the proximal anastomosis and perigraft seroma. Graft infection is a serious complication that may be accompanied by high moctality and amputation rates, s'7 Although these complications may be expected to occur at a certain rate whenever a prosthetic material is used, the reported rates after Ax-bFB (3% to 12%) are clearly higher than for all other prosthetic vascular bypass procedures. 4-s Upper-arm ischemia caused by thromboembolism originating from the proximal anastomosis is another disastrous event that is reported to occur in 15% of cases. L3-6 Amputation of otherwise asymptomatic arms has also been reported as a result of thromboembolism after Ax-bFB. ~ Because these events usually occur with occluded grafts, some investigators recommend the routine detachment of the graft from the native artery? Reoperative axillary surgery has yet another set of associated compfications. Because of these complications, the reoperation rate after Ax-bFB has been extremely high (35% to 44%). 4,6
Previously we reported an initial experience with EVGs for the treatment of bilateral aortoiliac occlusive disease in which we described the insertion of a separate EVG on each side.17-2°,22 Although the concept of bilateral iliac endovascular grafting appears simple, the practical requirements in performing bilateral iliac recanalization may be technically demanding, and a compromised result or even graft failure may be encountered. In contrast, because of the simplicity of the unilateral EVG procedure, a satisfactory proximal anastomosis can be achieved in most cases. In addition to the satisfactory results, this single iliac EVG technique significantly shortened the required intravascular maneuvering and likely reduced the possibility ofintraoperative complications. This is reflected in the short operative time (niean, 2.5 hr) and the minimal amount of blood loss (mean, 182 ml). Furthermore, because the placement of an FFB graft is lmown to double the blood flow of the donor iliac artery, one can expect that thc blood flow through thc single EVG will be twice the flow through bilateral EVGs? s,4° Given that high blood flow through a prosthetic graft may reduce the incidencc of thrombosis and anastomotic intimal hyperplasia, we believe that this may provide an additional advantage. With regard to the durability of the dilated PTFE graft, it has been shown that the PTFE graft can be used safely if the dilation ratio is less than 3:1.* Given that all of the inserted EVGs were surrounded and supported by native vessels and that the PTFE grafts were dilated only up to 1.2:1, we believe that the risk of further graft expansion, rupture, or both after insertion is negligible.
Technical success was achieved in 100% of the recanalization procedures attempted in this study without any procedural complications such as distal embolization. This is exceptional compared with the reported success rates and complication rates associated with balloon angioplasty with or without the insertion of vascular stents for the treatment of iliac occlusions. The technical success rates ofangioplasty with or without stenting have been reported to range between 33% and 81%. 13~6 Distal embolization has been reported to occur at rates of 5% to 20%, and the overall complication rate ranges between 1I% and 50%3 a16 The advantages of EVG procedures over these techniques become more apparent when considering the clinical state of the patients treated and the severity of their occlusive disease. These angloplasty series contained a high percentage of patients who had claudication as the indication for treatment (50% to 91%). The percentage of patients who had ischemic tissue loss as an indication for treatment was only 0% to 8%, and the mean lesion length was 5.1 to 6.4 cm. In comparison, our current study included only those patients who had ischemic tissue loss and a mean lesion length of 15.4 _+ 5.2 cm There axe severn factors that support the treatment of aortoiliac occlusive disease with EVGs rather than percutaneous angioplasty and stenting. When performing percutaneous angioplasty, arterial rupture during balloon dilatation will result in an acute procedural failure and necessitate surgical correction. It is for this reason that overdilatation should be avoided. 15 Avoiding overdilatation may prevent rupture, but it may also be partly responsible for the disappointing patency rates after percutaneous therapy because overdilatation of the lesion to overcome elastic recoil may be a crucial part of the procedure. In the current series, two arterial ruptures were detected during dilatation. These lesions, however, were safely excluded from the circulation by the insertion of an EVG. Accordingly, arterial perforation during vessel dilatation for EVG insertion did not result in a procedure complication and is likely to occur while cre-December 1996 Fig. 9 . A, Preoperative arteriogram of patient no. 5 demonstrates that the right iliac artery system is diffusely stenosed and occluded from its origin on the left side. Because the right internal iliac artery is negligible (type I), the right side was chosen for recanalization and graft I p s i -l a t e r a l to EVS C o n t r a -l a t e r a l to EVS Fig. 10 . Hemodynamic improvement after endovascular grafting. After EVG bypass procedure, thigh PVR amplitudes increased from 9 -3 mm to 30 + 7 mm on the side ipsilateral to EVG insertion and from 6 + 2 mm to 24 + 4 mm on the contralateral side.
ating a wide tract into which the EVG will be inserted. All procedures in the current study were performed through open access sites. This approach may reduce the chance for distal embolization because control of the inflow to the distal arteries can be uniformly obtained. Additional advantages to an "open" cut-down technique include the ability to perform this procedure even in the presence of a common femoral artery occlusion or when a standard infrainguinal bypass or associated procedure is required (i.e., endarterectomy, profimdaplasty).
We have successfully performed bilateral aortoiliac reconstructions by using an EVG combined with a standard FFB. Although the number of cases in which these combined techniques were used is limited, this technique appears to be a safe and effective alternative for treating bilateral multilevel occlusive disease, especially in patients who have contraindications to ABFB. Although an analysis of a larger group of patients over a longer period of time will be required to determine the long-term success, the short life expectancy of the high-risk population in this study may justify this approach to limb-threatening aortoiliac occlusive disease.
DISCUSSION
Dr. R. Clement Darling III (Albany, N.Y.). I would like to congratulate Dr. Ohld for his ~xcellent presentation, and I commend the group from Montefiore for their pioneering work in the field of stent gFafting. In this study, seven patients who had severe, multilevel peripheral vascular disease and critical ischemia were treated with the placement of unilateral stent grafts and crossover FFBs. These patients had significant comorbid diseases that placed them at substantial risk for undergoing general anesthesia combined with more extensive vascular surgery. The mortality rate in these seven patients was 0%. Technical success was achieved in 100%. Minimal blood loss was incurred. Overall the patients had a significant hemodynamic improvement. Two patients had perforation of external iliac arteries, which were treated with exclusion by the insertion of the endovascular device. These are truly laudable results in a very difficult patient population. I have a few questions for Dr. Ohki.
First, what were the exclusion criteria used for the selection of these patients? Were there any patients who were excluded because of anatomic or physiologic reasons such as small iliac arteries, aortic occlusion, or aortoiliac aneurysmal disease?
Second, how much dye was used in this procedure? Is this procedure contraindicated in patients who have chronic renal insufficiency, and how do you handle patients who may not be able to tolerate a substantial dye load?
Third, have you had any fixation problems with the proximal stent or with stent graft migration? In patients who have smaller distal arteries, have you had any problems with the distal anastomosis?
Also, in patients with extravasation of dye from the external iliac artery, is it usually handled with a stent graft? However, would this be possible with perforation occurring in the common iliac artery? If you used the stent graft to repair these, how would you deal with the hypogastric, especially with regard to retrograde flow that may leak out the perforation?
Finally, because your group has had such superb results with these severely ill patients, would you consider expanding the indications for this procedure to other patients?
In conclusion, I commend Dr. Veith's group on his tremendous results with these stent grafts, I think that this is a revolutionary procedure, and i look forward with great interest to the long-term and mid-term results as to the patency of these grafts.
Dr. Takao Ohki. No patients were excluded from the study for anatomic or physiologic reasons. The only patients who were excluded were those who were healthy enough to tolerate an ABFB. We had one patient who had a small iliac artery, but this was not an obstacle to performing the procedure. Although we did not encounter a case with a high aortic occlusion, it could be a contraindication, as Dr. Darling has pointed out, because the aorta might be filled with thrombus and maneuvering a gnidewire or a catheter within a thrombus has the potential of distal and, more importantly, proximal embolization. In the current series there were no cases with coexisting aortic aneurysms, but if we did encounter such a case, we could perform the so-called "Parodi procedure" to treat both the aneurysm and the occlusion. However, because the profile of the delivery system for an aneurysm is slightly larger than that used for occlusive disease, insertion of the device through a previously occluded lliac artery might be difficult.
Although the amount of contrast medium used in this study was small and postoperative renal failure did not develop in any of our patients, even a small amount of contrast dye may be harmful in the presence of severe renal failure. In such instances the surgeon must carefully weigh the benefits and the disadvantages of using an alternative procedure. Although an axiilofemoral bypass can be performed without using a contrast medium, the numerous disadvantages associated with this procedure must b e taken. into consideration.
We have not had a problem with stent migration or fixation when treating patients who have occlusive disease.
We are more concerned with these complications when performing endovascular grafting for aneurysmal disease.
Unlike some series that have been reported by interventional radiologists, our series dealt only with cases of ischemic gangrene. Hence, we had only three patients who had a common femoral artery that was suitable for anastomosis with the EVG; in the other four cases it was either occluded or severely diseased. Because each procedure was performed under direct exposure of the femoral vessels, dependmg on the amount of distal disease present, the distal anastomosis was easily fashioned. This fearure is a major advantage when compared with the percutaneous approach. If a hypogastric artery was feeding an arterial rupture site, we would deploy a second stent within the EVG at the origin of the hypogastric artery to tightly seal the graft to the arterial wall, thus occluding hypogastric retrograde flow. If this failed, the next optionwould be to obtain direct exposure through a retroperitoneal incision and ligate the feeding vessel. We believe that the ability of an EVG to safely treat these disrupted vessels is an advantage over conventional stenfing. We are, therefore, comfortable during balloon dilatation and do not consider iliac artery perforation as a complication, but rather a part of the procedure.
In regard to expanding the indications, we believe that this procedure is still experimental and that many questions need to be answered--the most important being long-term parency. Accordingly, until these questions are resolved, we do not plan on expanding the indications to include healthy patients with longer life expectancies who can tolerate the gold standard procedure, that is, an ABFB.
Dr. Jerry R. Youkey (Danville, Pa. j. It is my understanding that the application in this manner of these two combined items is perceived, at least previously, by the Food and Drug Administration (FDA ~, as an off-label use of the items, Were these studies done with Institutional Review Board approval on a compassionate-use basis? What would be your recommendations and perhaps your coauthors to those of us who would entertain doing these kinds of procedures in our instatutions in regard to not inviting the attention of the FDA, or perhaps even more importantly of avoiding what might be perceived as an almost indefensible suit? What are the liability issues if we have an untoward event?
Dr. Frank I. Veith. That is indeed a tough question. I think one of the reasons I queried Dorothy Abel so intensely was that the policy of the government up until now has been to accept off-label use and at least allow hospitals to charge for them. You will note that some previous papers clearly involved off-label use, including the use of the Wallstent in the axillary artery, so perhaps the question should be directed to others here rather than me. I thinl< our intention in the future is to get investigational device exemption-approval for all our off-label-use devices, and Dr. Marin and I are in the process of doing that. We are functioning in a capacity that is consistent with our institutional review board and up until now has been consistent with FDA and Health Care Financing Administration guidelines. But I think after what you heard, those guidelines are changing.
With regard to the legal liability, you can bet your tife that we, and any of you who try these procedures and have a bad outcome, are going to be very endangered by the potential of a lawsuit. It would be easy for a plaintiff's attorney to say: Are you using your device in an FDAapproved manner? The answer is no. You can predict what your own liability is going to be. I, therefore, would urge anybody who gets into this field to be aware of the rislcs involved, because they are real We have taken them and have not been burned yet, but the potential dearly exists. This is one of the stumbling blocks to moving ahead in this field.
Dr, Fredric Jarrett (Pittsburgh, Pa.). Do you or does anyone else in the audience know of any liability suits that have occurred with endovascular grafting, which obviously is still in its infancy?
Dr. Ohld. I do not know, but I am sure they do exist. We have been threatened by such suits, and fortunately they have not occurred. But the possibility is a major risk involved with using materials in an off-label fashion. However, it is done every day by every radiologist in the country who performs these procedures. The only stent that is approved for use is the P308, and other stents are being used routinely. So this is not just a problem that one faces in endovascular grafting. I am sure if you're using stents in your restitution, you are right in the same boat with everybody else who is using them off-label. So it is a real problem and one that has not yet been solved. [ therefore urge you to be careful. It is one of the reasons that we have not chosen to expand our indications and will not perform the procedures in a patient even if they have severe claudication and many other indications. We are afraid of the legal liability.
Dr. David Caleagno (Camp Hill, Pa.). I just have a technical quesnon, and I think I know how you would approach it because you described how you would approach a perforated iliac artery. It is pretty easy to get in a dissection plane when you're going up retrograde, and with your bilateral disease you can't do what they did and come up and over and work down. If you get in a dissection, are you comfortable with that as long as you pop back into the lumen, because you're using a graft as opposed to some of us that just do balloon dilation, or do yon abort the procedure?
Dr. Ohki. Ifa guidewire traverses the subintimal plane during recanalization, then using a directional catheter we try to reenter the true lumen before entering the aorta. Although this may not always be possible, it is more of a problem when one has to maintain contralateral iliac flow. Because we usually do not have to be concerned about contralateral flow. we can even place the proximal stent in the aorta and fix the dissection at the same time. Prograde recanalization through the axillary artery is another option. We have never had to abort a procedure because of this problem.
